查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1919317

聚合物心臟瓣膜市場：按產品類型、材質、應用和最終用戶分類 - 全球預測（2026-2032年）

Polymer Heart Valves Market by Product Type, Material Composition, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年聚合物心臟瓣膜市場價值為4.1927億美元，預計到2026年將成長至4.5087億美元，年複合成長率為5.35%，到2032年將達到6.0394億美元。

關鍵市場統計數據
基準年 2025 4.1927億美元
預計年份：2026年 4.5087億美元
預測年份 2032 6.0394億美元
複合年成長率 (%) 5.35%

本文簡要概述了影響聚合物心臟瓣膜創新和相關人員優先事項的當代臨床、監管和商業性趨勢。

聚合物心臟瓣膜領域融合了先進材料科學、微創心臟病學以及日益複雜的監管體系。本執行摘要總結了影響聚合物瓣膜器械臨床應用、生產策略和商業性定位的核心進展。其旨在為需要了解當前趨勢及其對未來決策的實際影響的高階主管、臨床負責人和策略投資者提供簡潔而又全面的資訊。

本文對正在重新定義聚合物閥門開發競爭優勢的技術、程序、監管和供應鏈轉折點進行了分析概述。

近年來，聚合物心臟瓣膜的評估方式發生了多項變革性變化。材料創新已超越了漸進式改進，新一代聚合物的研發旨在提高抗疲勞性、降低鈣化風險並實現更薄的瓣葉厚度。因此，先前仍處於臨床前階段的器械概念正逐步進入臨床評估階段，迫使相關人員和支付方重新評估其與外科組織瓣膜和機械瓣膜相比的價值提案。

重點分析累積關稅環境對聚合物心臟瓣膜價值鏈的籌資策略、生產韌性與資本配置決策的影響

2025年實施的關稅對聚合物心臟瓣膜生態系統產生了累積影響，重塑了成本結構和供應商選擇標準。由於關稅改變了進口聚合物基材和精密零件的相對競爭力，擁有全球供應鏈的製造商面臨投入要素波動性增加的問題。為應對這項挑戰，一些公司加快了近岸外包的步伐，以穩定利潤率並縮短物流前置作業時間；而另一些公司則透過談判長期合約和實現供應商多元化，來保護生產免受關稅暫時波動的影響。

深入的細分洞察揭示了產品類型、臨床應用、終端用戶環境和細微的材料成分如何共同影響設計檢驗和商業化路徑。

細分市場的細微差別會影響產品設計、臨床定位和客戶參與方面的實際選擇。按產品類型分類，市場涵蓋外科手術和經導管介入兩種選擇。外科手術策略進一步分為微創手術和開胸手術，而經導管介入方法則分為球囊擴張型和自擴張式輸送系統。設計人員必須將瓣葉材料特性與展開機制和預期的血流動力學負荷相匹配，並根據所選的輸送方式調整瓣葉厚度和支架相互作用。

區域趨勢和採納路徑表明，法規結構、報銷機制和臨床能力如何驅動世界不同地區差異化的市場進入策略。

區域趨勢影響監管策略、報銷方式和技術推廣速度，主要可分為三大區域：美洲、歐洲、中東和非洲以及亞太地區。在美洲，一體化的支付體系和集中的先進心臟病計畫為差異化技術的早期應用創造了有利環境，前提是開發商能夠提供令人信服的臨床證據和清晰的編碼路徑。同時，供應鏈因素和關稅風險正促使製造商考慮在該地區進行在地化生產，以保持成本競爭力並加快交付速度。

戰略競爭情報概述了專有材料、生產規模和臨床合作如何為聚合物閥門開發商創造永續的差異化優勢。

聚合物閥門領域的競爭格局呈現出垂直整合製造商、專業組件供應商和臨床合作者並存的局面。擁有專有聚合物配方或關鍵塗層或加工技術的公司能夠顯著提高市場進入門檻，尤其是在這些優勢與可靠的臨床前檢驗和清晰的生產規模化路徑相結合的情況下。器材開發商與材料科學公司之間的策略聯盟，透過智慧財產權共用和共同開發契約，能夠實現快速原型製作和迭代測試，從而加快部分專案的臨床應用進程。

為將材料創新、供應鏈韌性和證據生成轉化為切實可行的商業和臨床實施計劃，提出跨部門的可操作建議

優先考慮材料層面的差異化，使聚合物化學性質與預期的給藥方式和解剖應用相符。設計、工程和臨床團隊的早期協作可縮短迭代周期並加快檢驗里程碑的達成。這種整合方法可同時最佳化瓣膜動態、框架相互作用和滅菌途徑。

我們以透明的方式解釋我們的混合方法，該方法結合了初步訪談、系統的二次分析和嚴格的資料三角驗證，以確保可信度。

本研究整合了多種資訊來源和方法，對聚合物心臟瓣膜的現狀進行了透明且可重複的評估。主要研究包括對臨床醫生、企業採購人員、監管專家和材料科學家進行結構化訪談，以了解操作實踐、臨床偏好和市場進入的考量。訪談通訊協定採用統一的問題格式，以便對相關人員進行比較和進行主題分析。

摘要重點闡述了將材料和製程創新轉化為持續的臨床和商業性優勢的策略要務。

聚合物心臟瓣膜代表著材料工程、製程創新和不斷變化的監管要求三者交匯的策略轉折點。能夠將聚合物科學與切實可行的臨床路徑、穩健的生產策略和系統的證據生成相結合的機構，將抓住最具前景的機會。在這些領域取得卓越的執行力，將決定技術優勢能否轉化為持續的臨床應用和永續的經營模式。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的聚合物心臟瓣膜市場

  • 外科
    • 微創
    • 開胸手術
  • 經導管
    • 球囊擴張型
    • 自膨脹

9. 依材料成分分類的聚合物心臟瓣膜市場

  • 聚對苯二甲酸乙二酯
  • 聚氨酯脲
    • 醫用級聚氨酯
    • 熱塑性聚氨酯
  • 矽氧烷
    • 高強度矽膠
    • 醫用級矽膠

第10章 按應用分類的聚合物心臟瓣膜市場

  • 主動脈瓣
  • 二尖瓣
  • 肺動脈瓣
  • 三尖瓣

第11章 按最終用戶分類的聚合物心臟瓣膜市場

  • 門診手術中心
  • 醫院
    • 心臟專科醫院
    • 三級醫院
  • 專科診所

12. 各地區聚合物心臟瓣膜市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的聚合物心臟瓣膜市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國聚合物心臟瓣膜市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國聚合物心臟瓣膜市場

第16章：中國聚合物心臟瓣膜市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3F Therapeutics AG
  • Abbott Laboratories
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • CryoLife, Inc.
  • DirectFlow Medical, Inc.
  • Edwards Lifesciences Corporation
  • JenaValve Technology, Inc.
  • LivaNova PLC
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • Terumo Corporation
  • ValveMed Inc.
  • ValveXchange, Inc.
Product Code: MRR-F14BA1B341AE

The Polymer Heart Valves Market was valued at USD 419.27 million in 2025 and is projected to grow to USD 450.87 million in 2026, with a CAGR of 5.35%, reaching USD 603.94 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 419.27 million
Estimated Year [2026] USD 450.87 million
Forecast Year [2032] USD 603.94 million
CAGR (%) 5.35%

A concise high-level introduction that frames the contemporary clinical, regulatory, and commercial dynamics shaping polymer valve innovation and stakeholder priorities

The polymer heart valve sector sits at the intersection of advanced materials science, minimally invasive cardiology, and increasingly complex regulatory pathways. This executive summary synthesizes core developments shaping clinical adoption, manufacturing strategies, and commercial positioning for polymer-based valvular devices. It is written to inform senior executives, clinical leaders, and strategic investors who require a concise yet comprehensive view of current dynamics and practical implications for near-term decision making.

Across clinical settings, device developers are navigating a rapidly evolving evidence base that emphasizes durability, hemodynamic performance, and biocompatibility. At the same time, suppliers are confronting supply chain constraints, evolving reimbursement frameworks, and heightened scrutiny from regulators regarding long-term outcomes. These converging forces are accelerating strategic prioritization around material selection, delivery mode innovation, and post-market surveillance design. The subsequent sections translate these signals into actionable insights and operational recommendations that support product development, market entry, and portfolio management.

An analytical overview of the pivotal technological, procedural, regulatory, and supply chain shifts that are redefining competitive advantage in polymer valve development

Recent years have produced several transformative shifts that are recalibrating how stakeholders evaluate polymer heart valves. Material innovation has progressed beyond incremental improvements, with next-generation polymers designed to enhance fatigue resistance, reduce calcification potential, and enable thinner leaflet profiles. Consequently, device concepts that were once confined to preclinical demonstration are moving into clinical evaluation, prompting clinicians and payers to reassess comparative value propositions relative to surgical tissue and mechanical alternatives.

Concurrently, the procedural landscape is changing as transcatheter approaches expand anatomical reach and patient eligibility. Enhanced delivery systems and imaging integration have increased confidence among interventional teams, supporting broader adoption in centers with established structural heart programs. Supply chain restructuring constitutes another major shift; manufacturers are balancing global supplier networks with localized production strategies to mitigate trade disruptions and strengthen quality oversight. Regulatory authorities are also adapting, placing renewed emphasis on long-term real-world evidence and lifecycle management. Taken together, these shifts create both opportunity and executional complexity, underscoring the need for coordinated clinical, regulatory, and commercial strategies to realize durable patient and business outcomes.

A focused analysis of how the cumulative tariff landscape has influenced procurement strategies, production resilience, and capital allocation decisions across the polymer heart valve value chain

Tariff actions introduced in 2025 have exerted a cumulative effect on the polymer heart valve ecosystem by reshaping cost structures and supplier selection criteria. Manufacturers with globalized supply chains experienced increased input variability as duties altered the relative competitiveness of imported polymer substrates and precision components. In response, several firms accelerated nearshoring initiatives to stabilize margins and shorten logistics lead times, while others negotiated longer-term contracts or diversified supplier portfolios to shield production from episodic tariff volatility.

Beyond procurement, tariffs influenced capital allocation decisions. Investment in redundant production lines and intensified quality audits became a pragmatic response to mitigate interruption risk. Clinical trial management also felt indirect impacts, as device sponsors adjusted site budgets to account for higher import costs of specialty materials and tooling. Procurement teams and finance leaders have therefore prioritized scenario planning and tariff sensitivity analyses to preserve program timelines. Collectively, these developments have made resilience and flexibility central to commercial planning, encouraging cross-functional investments that balance cost containment with the need to maintain product integrity and regulatory compliance.

Deep segmentation insights that reveal how product type, clinical application, end user settings, and nuanced material compositions collectively shape design validation and commercial pathways

Segmentation nuance drives practical choices across product design, clinical positioning, and customer engagement. When differentiated by product type, the market encompasses Surgical approaches and Transcatheter options, with Surgical strategies further categorized into Minimally Invasive and Open Heart techniques while Transcatheter approaches distinguish between Balloon Expandable and Self Expandable delivery systems. Designers must therefore reconcile leaflet material properties with deployment mechanics and expected hemodynamic loading, tailoring leaflet thickness and frame interaction to the selected delivery modality.

Application-based segmentation into Aortic, Mitral, Pulmonary, and Tricuspid anatomies imposes distinct anatomical constraints and durability expectations. Each valve position presents unique calcification patterns, annular dynamics, and exposure to varying pressure regimes, which in turn influence preclinical test protocols and patient selection criteria. End user segmentation between Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, with Hospitals further differentiated into Cardiac Specialty Hospitals and Tertiary Care Hospitals, informs distribution, training, and support models. High-volume cardiac centers will prioritize integrated training and on-site technical support, whereas ambulatory settings emphasize streamlined logistics and predictable procedure times.

Material composition choices-spanning Polyethylene Terephthalate, Polyurethane Urea, and Siloxane-are at the core of performance and regulatory pathways. Polyurethane Urea is further understood through distinctions between Medical Grade PU and Thermoplastic PU, each offering different processing characteristics and fatigue profiles. Siloxane formulations are evaluated across High Strength Silicone and Medical Grade Silicone variants, with trade-offs between tensile properties and biostability. These material distinctions compel a systems-level approach to design verification, sterilization validation, and clinical data generation, ensuring that product positioning aligns with both procedural use cases and end-user expectations.

Regional dynamics and adoption pathways that map how regulatory frameworks, reimbursement mechanisms, and clinical capacity drive differentiated market access strategies across global geographies

Regional dynamics influence regulatory strategy, reimbursement approaches, and adoption velocity across three broad geographies: Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidated payer systems and a concentration of advanced cardiac programs create fertile ground for early adoption of differentiated technologies, provided developers present compelling clinical evidence and clear coding pathways. Conversely, supply chain considerations and tariff exposure have prompted manufacturers to evaluate localized production for this region to maintain cost competitiveness and shorten delivery cycles.

The Europe, Middle East & Africa region features heterogeneous regulatory regimes and reimbursement mechanisms, requiring tailored market access strategies. Centralized regulatory pathways in some European jurisdictions favor coordinated clinical dossiers and shared real-world evidence initiatives, while other markets within the region may prioritize cost-effectiveness demonstrations. In the Asia-Pacific context, rapid demographic shifts and expanding interventional cardiology capacity have increased demand, yet market entry strategies must account for local regulatory nuances, partner selection, and culturally specific adoption drivers. Across all regions, collaboration with leading clinical centers and phased evidence generation remain essential to translate technical differentiation into durable clinical and commercial outcomes.

Strategic competitive intelligence outlining how proprietary materials, manufacturing scale, and clinical partnerships create sustainable differentiation for polymer valve developers

Competitive dynamics in the polymer valve arena are characterized by a mix of vertically integrated manufacturers, specialized component suppliers, and clinical collaborators. Companies that secure proprietary polymer formulations or that control critical coating and processing technologies enjoy meaningful barriers to entry, especially when those assets are paired with robust preclinical validation and clear manufacturing scale-up pathways. Strategic partnerships between device developers and material science firms have accelerated time-to-clinic for some programs, as shared IP and co-development agreements enable rapid prototyping and iterative testing.

Market leaders are also distinguishing themselves through investments in quality systems, modular manufacturing footprints, and post-market evidence platforms. Firms that align clinical development with comprehensive post-market surveillance strategies are better positioned to respond to regulatory queries and to communicate long-term safety narratives to clinicians and payers. In addition, alliance activity-ranging from distribution agreements to targeted acquisitions of niche suppliers-reflects a broader push to control supply chain inputs and to offer bundled solutions that simplify adoption for hospital systems and specialty centers. These strategic moves are shaping a competitive landscape where technical differentiation must be supported by operational excellence and stakeholder trust.

Actionable, cross-functional recommendations that translate material innovation, supply resilience, and evidence generation into pragmatic commercial and clinical execution plans

Prioritize material-level differentiation that aligns polymer chemistry with the intended delivery modality and anatomical application. Early alignment between design, engineering, and clinical teams reduces iteration cycles and accelerates validation milestones. This integrated approach ensures that leaflet mechanics, frame interactions, and sterilization pathways are concurrently optimized.

Invest in flexible manufacturing capacity and quality systems that support both rapid scale-up and localization. Modular production cells and dual-sourcing strategies mitigate trade-related disruptions and enable responsive supply to diverse regional markets. Coupling these investments with robust supplier qualification practices minimizes operational risk.

Embed real-world evidence planning into the earliest clinical development stages. Define endpoints and registry partnerships that capture durability, reintervention rates, and quality-of-life measures relevant to payers and clinicians. A transparent evidence generation plan strengthens reimbursement discussions and post-market confidence.

Forge targeted clinical and commercial partnerships with centers of excellence and regional distributors to streamline training, proctoring, and launch execution. Tailored support models for ambulatory centers versus tertiary hospitals will increase procedure throughput and device adoption.

Adopt proactive regulatory engagement and lifecycle management strategies that anticipate post-market data expectations. Early dialogues with regulators can clarify acceptable evidence pathways and post-approval commitments, reducing downstream uncertainty.

Allocate resources to customer education and value communication that translate biophysical advantages into tangible clinical benefits. Case-based learning, simulation training, and peer-led outcomes dissemination build clinician confidence and drive referral patterns.

Monitor geopolitical and tariff trends continuously and develop scenario-based financial plans that preserve program agility. Engage cross-functional teams to reassess supplier terms and to model the operational implications of trade policy shifts.

Leverage strategic M&A selectively to acquire specialized polymer technologies, processing capabilities, or clinical infrastructure that complement existing portfolios. Integration should prioritize maintaining development velocity and protecting critical know-how.

A transparent description of the mixed-methods research approach that integrates primary interviews, systematic secondary analysis, and rigorous data triangulation to ensure reliability

This research synthesizes multiple sources and methods to produce a transparent, reproducible assessment of the polymer heart valve landscape. Primary research included structured interviews with clinicians, enterprise procurement leaders, regulatory experts, and materials scientists to capture operational realities, clinical preferences, and market access considerations. Interview protocols emphasized consistent questioning to enable cross-stakeholder comparison and thematic analysis.

Secondary research comprised systematic reviews of peer-reviewed clinical literature, regulatory guidance documents, and engineering test standards to map technical performance criteria and approval pathways. Supplier mapping and patent landscaping were performed to identify concentration risks and proprietary material advantages. Data triangulation was used throughout to reconcile divergent perspectives, and key findings were validated through follow-up interviews and cross-referencing with publicly available regulatory filings.

The methodology acknowledges limitations inherent in emerging technology assessment, including evolving clinical evidence and variable reporting standards. To mitigate these constraints, the study adopted conservative evidence weighting, highlighted areas of uncertainty, and recommended continuous monitoring of post-market registries and regulatory updates. Ethical safeguards and confidentiality protocols governed all primary engagements, ensuring candid stakeholder insights while protecting proprietary information.

A concluding synthesis that underscores the strategic imperatives for converting material and procedural innovation into durable clinical and commercial advantage

Polymer heart valves represent a strategic inflection point where materials engineering meets procedural innovation and evolving regulatory expectations. The most promising opportunities will be realized by organizations that integrate polymer science with pragmatic clinical pathways, robust manufacturing strategies, and disciplined evidence generation. Execution excellence across these domains will determine whether technological advantages translate into durable clinical adoption and sustainable business models.

Looking ahead, stakeholders should expect continued emphasis on long-term outcomes, device lifecycle transparency, and operational resilience. Developers who proactively address these imperatives-through collaborative clinical programs, flexible supply strategies, and clear communication of value-will enhance their ability to navigate competitive pressures and policy uncertainties. Ultimately, the pathway to success combines technical differentiation with disciplined commercialization and stakeholder-centric evidence frameworks.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Polymer Heart Valves Market, by Product Type

  • 8.1. Surgical
    • 8.1.1. Minimally Invasive
    • 8.1.2. Open Heart
  • 8.2. Transcatheter
    • 8.2.1. Balloon Expandable
    • 8.2.2. Self Expandable

9. Polymer Heart Valves Market, by Material Composition

  • 9.1. Polyethylene Terephthalate
  • 9.2. Polyurethane Urea
    • 9.2.1. Medical Grade Pu
    • 9.2.2. Thermoplastic Pu
  • 9.3. Siloxane
    • 9.3.1. High Strength Silicone
    • 9.3.2. Medical Grade Silicone

10. Polymer Heart Valves Market, by Application

  • 10.1. Aortic
  • 10.2. Mitral
  • 10.3. Pulmonary
  • 10.4. Tricuspid

11. Polymer Heart Valves Market, by End User

  • 11.1. Ambulatory Surgical Center
  • 11.2. Hospitals
    • 11.2.1. Cardiac Specialty Hospitals
    • 11.2.2. Tertiary Care Hospitals
  • 11.3. Specialty Clinics

12. Polymer Heart Valves Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Polymer Heart Valves Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Polymer Heart Valves Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Polymer Heart Valves Market

16. China Polymer Heart Valves Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3F Therapeutics AG
  • 17.6. Abbott Laboratories
  • 17.7. Biotronik SE & Co. KG
  • 17.8. Boston Scientific Corporation
  • 17.9. CryoLife, Inc.
  • 17.10. DirectFlow Medical, Inc.
  • 17.11. Edwards Lifesciences Corporation
  • 17.12. JenaValve Technology, Inc.
  • 17.13. LivaNova PLC
  • 17.14. Medtronic plc
  • 17.15. Meril Life Sciences Pvt. Ltd.
  • 17.16. Terumo Corporation
  • 17.17. ValveMed Inc.
  • 17.18. ValveXchange, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POLYMER HEART VALVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POLYMER HEART VALVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY OPEN HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY OPEN HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY OPEN HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SELF EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SELF EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SELF EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE PU, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE PU, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE PU, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY THERMOPLASTIC PU, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY THERMOPLASTIC PU, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY THERMOPLASTIC PU, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HIGH STRENGTH SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HIGH STRENGTH SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HIGH STRENGTH SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MITRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MITRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MITRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRICUSPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRICUSPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRICUSPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY CARDIAC SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY CARDIAC SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY CARDIAC SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 172. GCC POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 173. GCC POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 175. GCC POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 203. G7 POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 205. G7 POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. G7 POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. G7 POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 213. NATO POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 215. NATO POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. NATO POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)